Cyclophosphamide 100mg (DrugBank: Cyclophosphamide)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00326417 (ClinicalTrials.gov) | January 2006 | 12/5/2006 | Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) | Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) | Anemia, Aplastic | Drug: Fludarabine;Drug: Cyclophosphamide 150mg;Drug: Cyclophosphamide 100mg;Drug: Cyclophosphamide 50mg | Medical College of Wisconsin | National Heart, Lung, and Blood Institute (NHLBI);Blood and Marrow Transplant Clinical Trials Network;National Cancer Institute (NCI);National Marrow Donor Program | Completed | N/A | 65 Years | All | 97 | Phase 1;Phase 2 | United States |